Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amgen, J&J Propose New Target Range For Aranesp, Procrit

Executive Summary

Just a year after FDA removed information related to a dosing target range for erythropoiesis-stimulating agents from product labeling, Amgen and Johnson & Johnson are proposing to re-establish a specific hemoglobin target range for the anemia therapies

You may also be interested in...

ASCO/ASH Guideline Preserves Higher ESA Dosing Options For Cancer Patients

Despite the emergence of safety concerns related to use of erythropoiesis-stimulating agents in recent years, the American Society of Hematology and the American Society of Clinical Oncology are essentially providing the same dosing recommendations in their latest guideline for treatment of chemotherapy-induced anemia as in the previous version from five years ago

Amgen Seeking ESA Dosing Algorithm As Scripts Continue To Fall In Oncology

Amgen is taking steps to construct dosing algorithms for its erythropoiesis-stimulating agents that may help mitigate problems stemming from heterogeneous patient response to the anemia therapies

ESA Labeling Should Explain Hemoglobin Target, Advisory Committee Says

Treatment targets for erythropoiesis-stimulating agents in the renal setting need to be accompanied by clinical management information, FDA's Cardiovascular and Renal Drugs and Drug Safety and Risk Management Advisory Committees says

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts